Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]Product type:GuidanceProgramme:Technology appraisal guidanceExpected publication date: 24 May 2019
Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement (TA722)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 August 2021
Selective internal radiation therapies for treating hepatocellular carcinoma (TA688)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 31 March 2021
Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (TA666)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 December 2020
Ramucirumab for treating unresectable hepatocellular carcinoma after sorafenib (terminated appraisal) (TA609)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 30 October 2019
Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) (TA582)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 May 2019
Regorafenib for previously treated advanced hepatocellular carcinoma (TA555)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 9 January 2019
Lenvatinib for untreated advanced hepatocellular carcinoma (TA551)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 December 2018
Sorafenib for treating advanced hepatocellular carcinoma (TA474)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 September 2017
Durvalumab with tremelimumab for untreated unresectable hepatocellular carcinoma [ID2725]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 25 August 2021
Cabozantinib for previously treated advanced hepatocellular carcinoma [ID3917]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 14 December 2022
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: 24 April 2024
Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma [ID3930]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma ID3940Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement ID3992Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer [ID4031]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma TS ID 10503Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma TS ID 10757Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab for untreated unresectable hepatocellular carcinoma [ID4068]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Tislelizumab for untreated unresectable hepatocellular carcinoma TS ID 10683Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence TS ID 10650Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma TS ID 10736Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC